{"id":"metoprolol-succinate-doxazosin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Syncope"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2356097","moleculeType":"Small molecule","molecularWeight":"652.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metoprolol succinate is a beta-1 selective adrenergic antagonist that decreases heart rate, contractility, and blood pressure. Doxazosin is an alpha-1 adrenergic antagonist that causes vasodilation and reduces peripheral vascular resistance. Together, they provide complementary antihypertensive effects through different sympathetic nervous system pathways.","oneSentence":"This combination reduces blood pressure by blocking beta-adrenergic receptors (metoprolol) to decrease heart rate and cardiac output, while blocking alpha-1 adrenergic receptors (doxazosin) to relax blood vessels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:56.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure (metoprolol succinate component)"}]},"trialDetails":[{"nctId":"NCT01798992","phase":"PHASE4","title":"Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2000-09","conditions":"Idiopathic Dilated Cardiomyopathy","enrollment":56},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Toprol XL","Cardura","Carduran"],"phase":"marketed","status":"active","brandName":"Metoprolol succinate + doxazosin","genericName":"Metoprolol succinate + doxazosin","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure by blocking beta-adrenergic receptors (metoprolol) to decrease heart rate and cardiac output, while blocking alpha-1 adrenergic receptors (doxazosin) to relax blood vessels. Used for Hypertension, Heart failure (metoprolol succinate component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}